|Friday, 21 January 2011 06:27|
As difficult as the scientific process was, the business plan was simple. Odidi and cheap cialis his team worked out the chemical composition to develop the drugs and usa cialis pushed their versions through the regulatory process at the U.S. Food and Drug Administration. Once approved, the company licensed the drugs to different companies and viagra tablet weight collected royalties. While Odidi perfected his science and healthcare of canada pharmacy learned to navigate the FDA process, Biovail grew into a 10+billion market cap company.
You’d never notice him if you passed the Nigerian-born CEO on the street. Odidi is a quiet man whose demeanor and us viagra smile tend to understate his achievements and buy cialis no prescription brilliance. His work has been cited in textbooks, scientific and buy generic cialis medical papers and cialis samples countless articles, but it was his work at Biovail that caught the attention of Wall Street after he first founded Intellipharmaceutics as a private company with his wife and find cheap viagra colleague, Dr. Amina Odidi (an accomplished formulator and buy cialis without prescription scientist who some often refer to as the company's Secret Weapon), in 1998.
Several financiers and investors with an eye for developing publicly traded companies recognized that Odidi and his unique talents as a master formulator might be worth a bit more than a paycheck- perhaps billions more. Through a carefully crafted reverse-merger in 2009, they helped take the company public and best prices on cialis now, after careful incubation and cialis for order lab work, it appears their bet on Odidi is about to pay off in multiple ways.
That niche was targeted and controlled released drugs using a proprietary Hypermatrix technology.
While most drug delivery companies deal in three-dimensions, Odidi decided to expand his vision and approach to drug composition by introducing a fourth and fifth dimension: space and time. “After all, we are in the time release business, so we should be looking at how to control time,” says Odidi.
The result is what Odidi calls “super generics” - very good copies of drugs that are about to come off-patent and aim to make the original drug formulation better. According to Odidi, the technology allows him to deliver any active pharmaceutical ingredient to the body in the right amount at the right time.
As a result, Intellipharmaceutics has now filed approximately $6 billion of generic controlled released drugs with the FDA to date.
In anticipation of several key events, biotech investors have begun to buy up whatever shares they can get. Since we highlighted the company to our subscribers days ago, shares have nearly doubled and they look to go much higher for one simple reason. The float of available shares is nearly non-existent and those who have managed to purchase shares are simply not letting them go. The result is a developing “load and lock” investment play not unlike the one we saw when shares of a bankrupt Vermillion (VRML) go from pennies to over $30 per share based on a single catalyst event- an FDA approval last year.
If you look under the hood, IPCI has a nearly identical number of shares outstanding and a growing number of hands that are buying as many shares as they can with both hands as they eyeball a list of multiple drug candidates and a stream of anticipated 2011 events that may fast track the young company into a generics powerhouse:
As the technical analysis chart below shows, the stock is primed to continue running higher - especially when you consider that prices are now within acceptable ranges for institutional investors and funds who may have been either hesitant or simply unwilling to jump in previously.
(Click to enlarge)
In addition to everything else, we fully expect Intellipharmaceutics’ news flow to exceed the expectations outlined in this report given the fact that the company has a pipeline of twelve more drugs in various stages of development with a portfolio of 30+ patents issued and pending. Good luck finding a few shares to stash away.
Disclosure: Long IPCI